News from ico therapeutics inc

Jun 30, 2014, 07:00 ET

iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders

VANCOUVER, June 30, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced that all...

Jun 09, 2014, 08:00 ET

iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema

VANCOUVER, June 9, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced top-line...

May 29, 2014, 17:00 ET

iCo Therapeutics Announces First Quarter 2014 Financial Results

VANCOUVER, May 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results...

Apr 29, 2014, 07:00 ET

iCo Therapeutics Announces Poster Presentation at ARVO

VANCOUVER, April 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that research...

Apr 24, 2014, 17:00 ET

iCo Therapeutics Announces Year End 2013 Financial Results

VANCOUVER, April 24, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results...

Mar 05, 2014, 07:00 ET

iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study

VANCOUVER, March 5, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month...

Feb 25, 2014, 13:15 ET

iCo Therapeutics Announces DTC Approval

VANCOUVER, Feb. 25, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced that its...

Jan 27, 2014, 10:03 ET

iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing

VANCOUVER, Jan. 27, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) announced today that it has...

Jan 22, 2014, 08:42 ET

iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing

VANCOUVER, Jan. 22, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or the "Company") (TSX-V: ICO) (OTCQX: ICOTF) is pleased to announce today...

Jan 21, 2014, 17:00 ET

iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering

VANCOUVER, Jan. 21, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or the "Company") (TSXV: ICO) (OTCQX: ICOTF) announced today that it has...

Dec 20, 2013, 07:00 ET

iCo Therapeutics Begins Trading on the OTCQX Marketplace

VANCOUVER, Dec. 20, 2013 /PRNewswire/ - iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF), announced that its common shares will begin trading today on...

Dec 12, 2013, 11:42 ET

iCo Therapeutics Announces Program and Intellectual Property Advancements for Oral Amphotericin B

VANCOUVER, Dec. 12, 2013 /PRNewswire/ - iCo Therapeutics (TSX-V: ICO), today announced that on November 26, 2013, U.S. patent 8,592,382 was...

Sep 05, 2013, 17:06 ET

iCo Therapeutics Grants Options to a Director

VANCOUVER, Sept. 5, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO), today announced that on September 5, 2013 the...

Sep 04, 2013, 07:00 ET

iCo Therapeutics to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference

VANCOUVER, Sept. 4, 2013 /PRNewswire/ - iCo Therapeutics Inc. (TSX-V: ICO), today announced it will be presenting at the Rodman & Renshaw...

Aug 26, 2013, 17:00 ET

iCo Therapeutics Announces Second Quarter 2013 Financial Results

VANCOUVER, Aug. 26, 2013 /PRNewswire/ - iCo Therapeutics (TSX-V: ICO), today reported financial results for the quarter ended June 30, 2013....

Jun 18, 2013, 07:00 ET

iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema

VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed...

Sep 26, 2011, 07:45 ET

iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema

VANCOUVER, Sept. 26, 2011 /PRNewswire/ - iCo Therapeutics Inc. (TSXV: ICO) today announced that the company has entered into a research...

Dec 11, 2009, 09:00 ET

iCo Therapeutics Provides Phase 1 Diabetic Macular Edema (DME) Clinical Trial Update and Phase 2 Trial Guidance

VANCOUVER, Dec. 11 /PRNewswire-FirstCall/ - iCo Therapeutics Inc. (TSX-V: ICO) - iCo Therapeutics ("iCo") is pleased to announce that its Phase 1...

Feb 09, 2009, 16:30 ET

iCo Therapeutics Closes $1.3 Million Private Placement

VANCOUVER, Feb. 9 /PRNewswire-FirstCall/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce the completion of a $1,292,500 non-brokered...

Jan 22, 2007, 00:00 ET

iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema

VANCOUVER, Jan. 22 /PRNewswire/ - iCo Therapeutics Inc. announced today that the United States Food and Drug Administration (FDA) has accepted...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
ReportBuyer
Investor-Edge